User:Fouryearsold/Anti-ulcer agents

From Wikipedia, the free encyclopedia

Anti-ulcer agents are medications or supplements used to cure the damage of mucosal layer on organs to prevent the damage from further extending to deeper regions to cause complications.

Anti-ulcer medication for treating mouth ulcer is triamcinolone, a corticosteroid. Other anti-ulcer supplements include vitamin B2 and vitamin B12.

Antibiotics and agents to reduce gastric acid secretion are used in combinations to treat Helicobacter pylori (H. pylori)-induced peptic ulcer disease (PUD), an ulceration in the gastric region. Antibiotics include amoxicillin, clarithromycin and metronidazole. Bismuth subsalicylate is an antimicrobial agent of another drug class that can also be used to eradicate H. pylori for treating PUD. Agents for suppressing gastric acid secretion are proton-pump inhibitors (PPI), such as lansoprazole, pantoprazole, rabeprazole, omeprazole and esomeprazole.

Anti-ulcer agents to treat mouth ulcer[edit]

Triamcinolone, vitamin B2 and vitamin B12 can be used to treat mouth ulcer, which are confined, shallow, round to oval-shaped lesions that sometimes contain yellowish adherent central exudate and give a pain sensation.[1]

Triamcinolone[edit]

The chemical structure of triamcinolone.

Triamcinolone is a corticosteroid, which can be applied on the ulcerated region to cure mouth ulcer by its anti-inflammatory action.

Medical uses and available forms[edit]

Triamcinolone is mainly used to treat recurrent mild to moderate aphthous stomatitis, also known as mouth ulcer.[2] This medication should show anti-ulcer effect or repair of oral tissues in seven days. This corticosteroid is available in the formulation of oral paste.[2]

Mechanism of action[edit]

Triamcinolone exerts its anti-inflammatory effect by decreasing the formation, release and activity of inflammatory substances originated from human bodies.[3] By reducing the inflammation, it can achieve anti-ulcer effect.[3]

Adverse effects[edit]

Triamcinolone commonly cause local side effects only. The undesirable effects may be oral mucosa changes that breaks the inner mouth mucosal layer. The damage in the mucosa may also cause redness and irritation on the application area.[4] In rare situations, systemic side effects may occur. Serious adverse drug reactions of this corticosteroid are Cushing's syndrome, symptoms and signs include high blood glucose level, excretion of glucose in urine and weight gain.[4] These undesirable effects can be prevented by not applying triamcinolone in large area.[4]

Contraindications[edit]

Triamcinolone should not be used if patients have hypersensitivity to triamcinolone.[5] Moreover, patients with fungal, viral, or bacterial infections in the mouth or throat should not consider using this medication.[5]

Interactions[edit]

Triamcinolone may interact with medications which are CYP3A4 inhibitors. CYP3A4 inhibitor may decrease the break down of triamcinolone which increases its amount in patients' body to cause toxicity.[6] Examples of CYP3A4 inhibitors include clarithromycin, verapamil, ketoconazole and anti-viral drugs, including nirmatrelvir and ritonavir.[7] These medications should not be administered with triamcinolone as drug-drug interactions may result.[6][7]

Vitamin B2[edit]

The chemical structure of vitamin B2.

Vitamin B2 is a supplement for promoting cell growth.[8] It can treat mouth ulcer without causing serious side effects.

Medical uses and available forms[edit]

Vitamin B2, also known as riboflavin, can cure mouth ulcer.[8] The common formulation of vitamin B2 is in tablet form for oral administration.[9]

Mechanism of action[edit]

Vitamin B2 is essential for mucosal growth. Sufficient intake of vitamin B2 can repair the damaged oral tissues efficiently.[8] This can heal the mouth ulcer.

Adverse effects[edit]

Adverse effects of vitamin B2 are mild. A common side effect of taking vitamin B2 is the production of yellow-orange urine. To address this problem, drinking more water may help to reduce the colour intensity of urine.[10]

Contraindications[edit]

Contraindications of vitamin B2 is uncommon. [11]

Interactions[edit]

Interactions of vitamin B2 with other drugs is uncommon.[12]

Vitamin B12[edit]

Medical uses and available forms[edit]

The chemical structure of vitamin B12.

Vitamin B12 is a supplement that can heal mouth ulcer. [13] It exists in tablet formulation and can be taken orally. [14]

Mechanism of action[edit]

Vitamin B12 is essential for cell duplication and formation of blood cells.[13] It can promote cell growth to repair the ulcerated regions in the mouth.[13]

Adverse effects[edit]

Oral administration of vitamin B12 may increase infection risks.[15] Side effects in other body systems are uncommon for oral formulation.[15]

Contraindications[edit]

Patients with hypersensitivity to vitamin B12 should not take the vitamin B12 supplement.[16]

Interactions[edit]

Heavy alcohol consumption over 2 weeks may decrease vitamin B12 absorption, which may reduce the effectiveness of this anti-ulcer agent.[14] Vitamin B12 may also interact with other medications. The therapeutic effect of this supplement may be reduced by chloramphenicol.[16]

Anti-ulcer agents to treat peptic ulcer disease (PUD)[edit]

Several anti-ulcer dosing regimens that combine antibiotics and proton pump inhibitors (PPI) to treat helicobacter pylori (H. pylori) induced peptic ulcer disease (PUD). The role of antibiotic in the therapies is to eradicate H. pylori, while the action of PPI is to reduce gastric acid secretion. The anti-ulcer dosing regimens generally repair the injury of gastric mucosal layer in PUD.

Examples of dosing regimen: [17]

  1. Amoxicillin + clarithromycin + PPI
  2. Bismuth subsalicylate + tetracycline + metronidazole + PPI
  3. PPI + amoxicillin for 5 days, then PPI + clarithromycin + metronidazole for 5 days

All therapies last for at least 2 weeks.[18] Ulcerations that remain active beyond 2 weeks may require longer treatment period.[18]

Antibiotics[edit]

For all antibiotics, patients need to finish the whole course of treatment to prevent antimicrobial resistance.[19] Recurrent ulceration may occur if H. pylori is not eradicated.[19]

Amoxicillin 500mg capsule.

Amoxicillin[edit]

Amoxicillin is an antibiotic that can be used in combination with other drugs to cure PUD.[20] Amoxicillin has a minimal resistance rate in H. Pylori of 2% worldwide.[21] This agent is used in first line treatment unless contraindicated.[20]

Medical uses and available forms[edit]

Amoxicillin is a penicillin antibiotic.[22] One of its indications is to eradicate H. pylori.[23] It is available as oral capsules.[24]

Mechanism of action[edit]

Amoxicillin can inhibit cell wall mucopeptide biosynthesis, leading to bacterial death.[23] This can reduce the ulcer recurrence risk.[25]

Adverse effects[edit]

Amoxicillin may cause gastrointestinal discomfort, namely nausea and vomiting.[26] To eliminate these adverse effects, take the medication after a meal. Besides, this antibiotic may disrupt bowel microflora and induce diarrhea.[27] In rare cases, amoxicillin may induce risk of Clostridium difficile-associated diarrhea.[26][28]

Contraindications[edit]

Patients with hypersensitivity or drug allergy to amoxicillin or other beta-lactams should not use this drug.[29]

Interactions[edit]

Patients using allopurinol may increase risk of allergic reactions.[30] Allergic responses range from skin rash to anaphylaxis.[30]

Clarithromycin[edit]

Clarithromycin is an antibiotic used in combined therapies for treating PUD.[31] Given the resistance of clarithromycin is higher than 15% in all WHO regions, it is still being used for eradicating H. pylori.[32]

Medical uses and available forms[edit]

Clarithromycin is an antibiotic under the class of macrolide.[33] It is indicated for the eradication of H. pylori to minimize the probability of duodenal ulcer recurrence by being a component of the combination therapy.[31][34] Clarithromycin is available as tablets which should be taken orally.[35][36][37]

Mechanism of action[edit]

Clarithromycin binds to the P site of 50S ribosomal subunit reversibly, which inhibits both the RNA-dependent protein synthesis and bacterial growth.[38] This reversible inhibition can kill the H. pylori in the gastric region.[38]

Adverse effects[edit]
Patient's appearance of the jaundice side effect.

Clarithromycin may cause gastrointestinal adverse effects including vomiting, nausea, taste alteration and abdominal pain.[39] This medication can also cause liver toxicity.[39] Symptoms of liver damage include anorexia, dark urine, jaundice, tender abdomen and pruritus.[39] To assess the liver function, ALT/AST should be closely monitored.[39] This antibiotic may also induce rare side effects in the cardiovascular system, such as QT prolongation, which may precipitate arrhythmia.[39][40]

Contraindications[edit]

Patients with hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibiotics should not take this medication.[41] Additionally, if patients are diagnosed with liver dysfunction before the treatment, clarithromycin is also contraindicated.[41]

Interactions[edit]

Clarithromycin should not be taken with CYP3A4 inhibitors, for instance, atorvastatin, amlodipine and warfarin.[42] Specifically, statins should be stopped for the period of therapy and resumed once H. Pylori is eradicated.[43]

Metronidazole[edit]

Metronidazole is an antibiotic with an off-label use in eradicating H. pylori for treating gastric ulceration. Resistance of metronidazole is above 15% worldwide.[32] It is likely to be resistant so is not the first line choice of treatment.[44] However, resistance is variable, that can be overcome by high dosages and in combination with other antibiotics.[45]

Medical uses and available forms[edit]

Metronidazole is an nitroimidazole antibiotic which can treat PUD.[44] Metronidazole as available as tablets for oral administration.

Mechanism of action[edit]
Patient's appearance of Steven-Johnson syndrome.

Metronidazole inhibits nucleic acid synthesis by disrupting DNA and breaking the strand of the bacteria. This kills the H. pylori.[46]

Adverse effects[edit]

The metronidazole tablet may have an unpleasant metallic taste, deteriorating drug compliance.[47] This medication may also induce rare side effect in the central nervous system, including neurotoxicity (encephalopathy, peripheral neuropathy, seizure).[48][49][50][51]

Contraindications[edit]

Patients should not drink alcohol to prevent disulfiram-like reactions, with symptoms of flushing, tachycardia, palpitations, nausea, vomiting.[51] Alcohol should only be taken at least 3 days after the last dose of metronidazole.[52][53]

Interactions[edit]

Metronidazole should not be used with carbocisteine due to the enhancement of carbocisteine toxicity.[54] Metronidazole also interacts with mebendazole to increase the risk of severe skin response like toxic epidermal necrolysis and Steven-Johnson syndrome[54]

Other antimicrobial drugs[edit]

Bismuth subsalicylate[edit]

The chemical structure of bismuth subsalicylate.

Bismuth subsalicylate is an antimicrobial drug in the off-labelled dosing regimen for H. pylori-induced PUD.[55] Its indication is to eradicate H. Pylori.[56]

Medical uses and available forms[edit]

Bismuth subsalicylate exists in the form of tablets and should be administered orally.[35][57]

Mechanism of action[edit]

Bismuth subsalicylate consists of the bismuth and subsalicylate moiety. The bismuth in bismuth subsalicylate has antibacterial activity against H pylori.[35] The salicylate moiety stimulates prostaglandins and exerts local gastroprotective effects.[56]

Adverse effects[edit]

Common side effect is darkening of the tongue and teeth.[58] It also causes darkening of faeces which may confuse with the signs of gastrointestinal bleeding.[59] In renal failure patients, long-term use of bismuth may cause toxicity, resulting in encephalopathy (ataxia, headache, confusion, seizures).[58]

Contraindications[edit]

Patients who are allergic to aspirin or taking other salicylates should not use bismuth salicylate.[59]

Interactions[edit]

As bismuth binds to food and experiences a reduction of efficacy, patients should take the medication on an empty stomach.[60]

Proton pump inhibitor (PPI)[edit]

Proton pump inhibitor (PPI) is a group of medications that reduce secretion of gastric acid to prevent further deterioration of gastric ulceration.[61]

Medical uses and available forms[edit]

PPI exist in the forms of oral enteric coated tablets or enteric granules capped within capsules. To ensure the effectiveness of the medication, patients should swallow the whole tablet.[62] They should not chew or cut the tablets, nor open the capsule and grind the granules.[62] To add on, patients should take the medicine 30 to 60 minutes before meals.[63]

The chemical structure of lansoprazole.

Different medications in this class has different standard doses:[35][36]

Medication Dosage
Lansoprazole 30mg
Omeprazole 20mg
Pantoprazole 40mg
Rabeprazole 20mg
Esomeprazole 20mg
Mechanism of action[edit]
The mechanism of action of proton pump inhibitors in a gastric parietal cell.

PPI irreversibly inhibits H+/K+ ATPase proton pump on gastric parietal cell to create profound, long-lasting antisecretory effect on gastric acid.[61][64]

Adverse effects[edit]

PPI may induce common side effects including headache, diarrhoea, abdominal pain and nausea. Taking PPI may rarely cause community acquired pneumonia. Prolonged use of PPI may be associated with intestinal clostridium difficile infection , low magnesium level, Vitamin B12 and iron deficiency, osteoporosis, acute kidney inflammation, and gastric cancer.[65][66][67][68][69][70]

Contraindications[edit]

Patients who have hypersensitivity to PPIs, or using products containing rilpivirine concomitantly should not take PPI.[71]

Interactions[edit]

Due to drug-drug interactions, patients taking clopidogrel, an antiplatelet drug, should not take PPI except rabeprazole.[72] Since PPI changes the acidity of the gastric content, patients taking ketoconazole, atazanavir, iron, erlotinib, and MMF should not take PPI at the same time.[72][73]

References[edit]

  1. ^ "Oral lesions. Aphthous ulcerations". UpToDate. 2024 Apr 1. {{cite web}}: Check date values in: |date= (help)
  2. ^ a b Taylor, Jennifer; Glenny, Anne-Marie; Walsh, Tanya; Brocklehurst, Paul; Riley, Philip; Gorodkin, Rachel; Pemberton, Michael N (2014-09-25), The Cochrane Collaboration (ed.), "Interventions for the management of oral ulcers in Behçet's disease", Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, doi:10.1002/14651858.cd011018.pub2, PMC 6872426, PMID 25254615, retrieved 2024-04-08{{citation}}: CS1 maint: PMC format (link)
  3. ^ a b "Triamcinolone (topical): Drug information. Pharmacology: Mechanism of action". UpToDate. Retrieved 2024-03-29.
  4. ^ a b c "Triamcinolone (topical): Drug information. Adverse reactions". UpToDate. Retrieved 2024-03-29.
  5. ^ a b "Triamcinolone (topical): Drug information. Contraindications". UpToDate.
  6. ^ a b "Triamcinolone (topical): Drug information. Interactions: Drug interactions". UpToDate. Retrieved 2024-03-29.
  7. ^ a b "Antivirals (Corticosteroids - interactions of corticosteroids)". Martindale. Retrieved 2024-03-29.
  8. ^ a b c Park, KK; Brodell, RT; Helms, SE (2011 Jul.). "Angular cheilitis, part 2: nutritional, systemic, and drug-related causes and treatment". Cutis. PMID 21877503. {{cite web}}: Check date values in: |date= (help)
  9. ^ "Vitamin B2 (riboflavin): Drug information. Dosing". UpToDate. Retrieved 2024 Apr 1. {{cite web}}: Check date values in: |access-date= (help)
  10. ^ "Vitamin B2 substances: Adverse effects and precautions". Martindale. Retrieved 2024-03-29.
  11. ^ "Vitamin B2 (riboflavin): Drug information. Contraindications/warnings". UpToDate. Retrieved 2024 Apr 4. {{cite web}}: Check date values in: |access-date= (help)
  12. ^ "Vitamin B2 (riboflavin): Drug information. Drug interactions". UpToDate. Retrieved 2024 Apr 4. {{cite web}}: Check date values in: |access-date= (help)
  13. ^ a b c Mousavi, Tahoora; Jalali, Hossein; Moosazadeh, Mahmood (2024-03-16). "Hematological parameters in patients with recurrent Aphthous Stomatitis: a systematic review and meta-analysis". BMC Oral Health. 24 (1). doi:10.1186/s12903-024-04072-5. ISSN 1472-6831. PMC 10943797. PMID 38493289.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  14. ^ a b "Cyanocobalamin (vitamin B12): Drug information. Dosing: Adult". UpToDate. Retrieved 2024-03-29.
  15. ^ a b "Cyanocobalamin (vitamin B12): Drug information. Adverse reactions". UpToDate. Retrieved 2024-03-29.
  16. ^ a b "Cyanocobalamin (vitamin B12): Drug information. Drug interactions". UpToDate. Retrieved 2024-03-29.
  17. ^ Wells, BG; Schwinghammer, TL; DiPiro, JT; DiPiro, CV (2017). Pharmacotherapy Handbook, 10th Edition. Peptic ulcer disease. McGraw-Hill Education. ISBN 978-1-259-58643-9.
  18. ^ a b Gisbert, J. P.; Pajares, J. M. (2005-04). "Systematic review and meta‐analysis: is 1‐week proton pump inhibitor‐based triple therapy sufficient to heal peptic ulcer?". Alimentary Pharmacology & Therapeutics. 21 (7): 795–804. doi:10.1111/j.1365-2036.2005.02418.x. ISSN 0269-2813. {{cite journal}}: Check date values in: |date= (help)
  19. ^ a b "Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects. Mechanisms of bacterial resistance". Uptodate. Retrieved 2024-04-04.
  20. ^ a b "Amoxicillin: Drug information. Use: Labeled Indications". Uptodate. Retrieved 2024-04-03.
  21. ^ Hooi, James K.Y.; Lai, Wan Ying; Ng, Wee Khoon; Suen, Michael M.Y.; Underwood, Fox E.; Tanyingoh, Divine; Malfertheiner, Peter; Graham, David Y.; Wong, Vincent W.S.; Wu, Justin C.Y.; Chan, Francis K.L.; Sung, Joseph J.Y.; Kaplan, Gilaad G.; Ng, Siew C. (2017-08). "Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis". Gastroenterology. 153 (2): 420–429. doi:10.1053/j.gastro.2017.04.022. {{cite journal}}: Check date values in: |date= (help)
  22. ^ "Amoxicillin: Drug information. Pharmacologic Category". Uptodate. Retrieved 2024-04-01.
  23. ^ a b "Amoxicillin: Drug information. Mechanism of Action". Uptodate. Retrieved 2024-04-01.
  24. ^ "Amoxicillin: Drug information. Dosage Forms: US". Uptodate. Retrieved 2024-04-03.
  25. ^ "Amoxicillin: Drug information. Use: Labeled Indications". Uptodate. Retrieved 2024-04-01.
  26. ^ a b "Amoxicillin: Drug information. Adverse Reactions (Significant): Considerations". Uptodate. Retrieved 2024-04-01.
  27. ^ Zhou, Hong; Xu, Qiang; Liu, Yu; Guo, Li-Tao (2020-05-26). "Risk factors, incidence, and morbidity associated with antibiotic-associated diarrhea in intensive care unit patients receiving antibiotic monotherapy". World Journal of Clinical Cases. 8 (10): 1908–1915. doi:10.12998/wjcc.v8.i10.1908. ISSN 2307-8960.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  28. ^ Connelly, Sheila; Subramanian, Poorani; Hasan, Nur A.; Colwell, Rita R.; Kaleko, Michael (2018-10). "Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome". Anaerobe. 53: 82–93. doi:10.1016/j.anaerobe.2018.04.012. {{cite journal}}: Check date values in: |date= (help)
  29. ^ "Amoxicillin: Drug information. Contraindications". Uptodate. Retrieved 2024-04-03.
  30. ^ a b "Amoxicillin: Drug information. Drug Interactions". Uptodate. Retrieved 2024-04-03.
  31. ^ a b "Clarithromycin: Drug information. Use: Labeled Indications". Uptodate. Retrieved 2024-04-01.
  32. ^ a b Savoldi, Alessia; Carrara, Elena; Graham, David Y.; Conti, Michela; Tacconelli, Evelina (2018-11). "Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions". Gastroenterology. 155 (5): 1372–1382.e17. doi:10.1053/j.gastro.2018.07.007. PMC 6905086. PMID 29990487. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link)
  33. ^ "Clarithromycin: Drug information. Pharmacologic Category". Uptodate. Retrieved 2024-04-01.
  34. ^ "Clarithromycin. Uses and Administration". Martindale. Retrieved 2024-04-01.
  35. ^ a b c d Chey, William D; Leontiadis, Grigorios I; Howden, Colin W; Moss, Steven F (2017-02). "ACG Clinical Guideline: Treatment of Helicobacter pylori Infection". American Journal of Gastroenterology. 112 (2): 212–239. doi:10.1038/ajg.2016.563. ISSN 0002-9270. {{cite journal}}: Check date values in: |date= (help)
  36. ^ a b Fallone, Carlo A.; Chiba, Naoki; van Zanten, Sander Veldhuyzen; Fischbach, Lori; Gisbert, Javier P.; Hunt, Richard H.; Jones, Nicola L.; Render, Craig; Leontiadis, Grigorios I.; Moayyedi, Paul; Marshall, John K. (2016-07). "The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults". Gastroenterology. 151 (1): 51–69.e14. doi:10.1053/j.gastro.2016.04.006. {{cite journal}}: Check date values in: |date= (help)
  37. ^ "Clarithromycin: Drug information. Dosing: Adult". Uptodate. Retrieved 2024-04-01.
  38. ^ a b "Clarithromycin: Drug information. Mechanism of Action". Uptodate. Retrieved 2024-04-01.
  39. ^ a b c d e "Clarithromycin: Drug information.Adverse Reactions". Uptodate. Retrieved 2024-04-01.
  40. ^ "Clarithromycin. Adverse Effects and Precautions". Martindale. Retrieved 2024-04-01.
  41. ^ a b "Clarithromycin: Drug information. Contraindications". UpToDate. Retrieved 2024 Apr 4. {{cite web}}: Check date values in: |access-date= (help)
  42. ^ "Clarithromycin: Drug information. Drug Interactions". Uptodate. Retrieved 2024-04-01.
  43. ^ "Statins + Macrolides. Importance and Management". Stockley's Drug Interactions. Retrieved 2024-04-01.
  44. ^ a b "Metronidazole (systemic): Drug information. Dosing: Adult". Uptodate. Retrieved 2024-04-01.
  45. ^ "Metronidazole. Antimicrobial Action". Martindale. Retrieved 2024-04-01.
  46. ^ "Metronidazole (systemic): Drug information. Mechanism of Action". Uptodate. Retrieved 2024-04-01.
  47. ^ "Metronidazole (systemic): Drug information. Adverse Reactions". Uptodate. Retrieved 2024-04-01.
  48. ^ Sørensen, Caspar Godthaab; Karlsson, William Kristian; Amin, Faisal Mohammad; Lindelof, Mette (2020-01). "Metronidazole-induced encephalopathy: a systematic review". Journal of Neurology. 267 (1): 1–13. doi:10.1007/s00415-018-9147-6. ISSN 0340-5354. {{cite journal}}: Check date values in: |date= (help)
  49. ^ Diodato, Daria; Olivieri, Giorgia; Pro, Sefano; Maiorani, Daniela; Martinelli, Diego; Deodato, Federica; Taurisano, Roberta; Di Capua, Matteo; Dionisi-Vici, Carlo (2018-09-18). "Axonal peripheral neuropathy in propionic acidemia: A severe side effect of long-term metronidazole therapy". Neurology. 91 (12): 565–567. doi:10.1212/WNL.0000000000006209. ISSN 0028-3878.
  50. ^ Kuriyama, Akira; Jackson, Jeffrey L.; Doi, Asako; Kamiya, Toru (2011-11). "Metronidazole-Induced Central Nervous System Toxicity: A Systematic Review". Clinical Neuropharmacology. 34 (6): 241–247. doi:10.1097/WNF.0b013e3182334b35. ISSN 0362-5664. {{cite journal}}: Check date values in: |date= (help)
  51. ^ a b "Metronidazole (systemic): Drug Information. Adverse Reactions (Significant): Considerations". Uptodate. Retrieved 2024-04-01.
  52. ^ Alonzo, Morgan M.; Lewis, Teresa V.; Miller, Jamie L. (2019-09-01). "Disulfiram-like Reaction With Metronidazole: An Unsuspected Culprit". The Journal of Pediatric Pharmacology and Therapeutics. 24 (5): 445–449. doi:10.5863/1551-6776-24.5.445. ISSN 1551-6776. PMC 6782120. PMID 31598109.{{cite journal}}: CS1 maint: PMC format (link)
  53. ^ Cina, Stephen J.; Russell, Roger A.; Conradi, Sandra E. (1996-12). "Sudden Death Due to Metronidazole/Ethanol Interaction:". The American Journal of Forensic Medicine and Pathology. 17 (4): 343–346. doi:10.1097/00000433-199612000-00013. ISSN 0195-7910. {{cite journal}}: Check date values in: |date= (help)
  54. ^ a b "Metronidazole (systemic): Drug information. Drug interactions". UpToDate.
  55. ^ "Bismuth subsalicylate: Drug information. Off-label: Adult". Uptodate. Retrieved 2024-04-01.
  56. ^ a b "Bismuth subsalicylate: Drug information. Mechanism of Action". Uptodate. Retrieved 2024-04-01.
  57. ^ "Bismuth subsalicylate: Drug information. Dosage Forms: US". Uptodate. Retrieved 2024-04-03.
  58. ^ a b "Bismuth subsalicylate: Drug information. Adverse Reactions". Uptodate. Retrieved 2024-04-01.
  59. ^ a b "Bismuth subsalicylate: Drug information. Contraindications". Uptodate. Retrieved 2024-04-01.
  60. ^ "Bismuth compounds + Food. Clinical evidence, mechanism, importance and management". Stockley's Drug Interactions. Retrieved 2024-04-01.
  61. ^ a b "Omeprazole: Drug information. Mechanism of Action". Uptodate. Retrieved 2024-04-01.
  62. ^ a b "Omeprazole. Directions for administration". British national formulary. Retrieved 2024 Apr 4. {{cite web}}: Check date values in: |access-date= (help)
  63. ^ Hershcovici, Tiberiu; Fass, Ronnie (2010-12). "An algorithm for diagnosis and treatment of refractory GERD". Best Practice & Research Clinical Gastroenterology. 24 (6): 923–936. doi:10.1016/j.bpg.2010.10.004. {{cite journal}}: Check date values in: |date= (help)
  64. ^ "Omeprazole. Uses and Administration". Martindale. Retrieved 2024-04-01.
  65. ^ Leonard, Jennifer; Marshall, John K.; Moayyedi, Paul (2007-09). "Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression". The American Journal of Gastroenterology. 102 (9): 2047–2056. doi:10.1111/j.1572-0241.2007.01275.x. ISSN 0002-9270. {{cite journal}}: Check date values in: |date= (help)
  66. ^ Aydın Yoldemir, Şengül; Zeren Ozturk, Guzin; Akarsu, Murat; Ozcan, Mustafa (2022-02). "Is there a correlation between hypomagnesemia linked to long-term proton pump inhibitor use and the active agent?". Wiener klinische Wochenschrift. 134 (3–4): 104–109. doi:10.1007/s00508-021-01834-x. ISSN 0043-5325. {{cite journal}}: Check date values in: |date= (help)
  67. ^ Lam, Jameson R.; Schneider, Jennifer L.; Zhao, Wei; Corley, Douglas A. (2013-12-11). "Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B 12 Deficiency". JAMA. 310 (22): 2435. doi:10.1001/jama.2013.280490. ISSN 0098-7484.
  68. ^ Nassar, Yousef; Richter, Seth (2018). "Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis". Journal of Bone Metabolism. 25 (3): 141. doi:10.11005/jbm.2018.25.3.141. ISSN 2287-6375. PMC 6135649. PMID 30237993.{{cite journal}}: CS1 maint: PMC format (link)
  69. ^ Ricketson, J.; Kimel, G.; Spence, J.; Weir, R. (2009-03-03). "Acute allergic interstitial nephritis after use of pantoprazole". Canadian Medical Association Journal. 180 (5): 535–538. doi:10.1503/cmaj.080456. ISSN 0820-3946. PMC 2645468. PMID 19255077.{{cite journal}}: CS1 maint: PMC format (link)
  70. ^ "Omeprazole: Drug information. Warnings/Precautions". Uptodate. Retrieved 2024-04-01.
  71. ^ "Omeprazole: Drug information. Contraindications". Uptodate. Retrieved 2024-04-03.
  72. ^ a b "Omeprazole: Drug information. Drug Interactions". Uptodate. Retrieved 2024-04-01.
  73. ^ Schaier, M.; Scholl, C.; Scharpf, D.; Hug, F.; Bonisch-Schmidt, S.; Dikow, R.; Schmitt, W. H.; Schwenger, V.; Zeier, M.; Sommerer, C. (2010-11-01). "Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil". Rheumatology. 49 (11): 2061–2067. doi:10.1093/rheumatology/keq238. ISSN 1462-0324.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Fouryearsold/Anti-ulcer_agents&oldid=1217908456"